Abstract-Leukotriene A4 hydrolase (LTA4H) is a hydrolase with a bifunctional zinc enzyme, which plays a role in inflammation. LTA4H may also play an important role in carcinogenesis, especially chronic inflammation-associated carcinogenesis. In this study, chemical feature based pharmacophore models based on 22 currently available LTA4H inhibitors have been developed with the aid of HipHop and HypoRefine modules within Catalyst program package. 3D pharmacophore model developed was, characterized by distinct chemical features such as Hydrogen-bond acceptor (HA), Hydrogen-bond donor (HD), Hydrophobic aliphatic (HPAli), Hydrophobic aromatic (HPAr) that are found to be responsible for the activity of the LTA4H inhibitors. The correlation coefficient, root mean square deviation and cost difference were 0.92, 1.0867 and 53.62 respectively, suggesting that a highly predictive pharmacophore model was successfully obtained. The results of our study provide a valuable tool in designing new leads with desired biological activity for virtual screening.
Introduction
Leukotriene A4 Hydrolase as a potent inhibitor in inflammation and cancer [1] [2] [3] Leukotriene A4 hydrolase, also known as LTA4H is a human gene. The protein encoded by this gene, a bifunctional zinc enzyme converts leukotriene A4 to leukotriene B4 (LTB4). LTA4H may play an important role in carcinogenesis, especially chronic inflammation associated carcinogenesis by two ways a) The inflammation augmenting effect of inflammatory cells b) The autocrine growth-stimulatory effect of LTB4 produced by epithelial cells and the paracrine growth stimulatory effect of LTB4 produced by inflammatory cells, on pre-cancerous and cancer cells. Many drugs like Bestatin (N-[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]-L-leucine), Thioamine (3-(4-benzyloxyphenyl)-2-(R)-amino-1-propane thiol)hydroxamic acid((N-hydroxy-N-[(2S)-2-amino-3-(benzyloxyphenyl)propyl]-5-carboxypentanamide) are available in the market which inhibits hydrolase activity. The variability in potency found in LTA4H inhibitors (IC50 ranging from sub-micromolar to high micromolar values for structurally related molecules) suggests that accessory binding pockets in the enzyme active site must be present and play a pivotal, still unclarified role in determining the affinity. It is therefore conceivable that the identification of such areas can be exploited for the design of novel, more potent LTA4H inhibitors. In view of the potential therapeutic importance of LTA4H inhibitors, we engaged ourselves in a program devoted to design feature based threedimensional pharmacophore model for LTA4H inhibitors. In this frame, we report a molecular modeling study aimed at mapping the topography of the active site of LTA4H and at identifying the structural requirement for LTA4H inhibition. Many LTA4H inhibitors for which biological values are available were collected from the literature along with their inhibitory IC50 values. The Generated model can be further utilized for developing new potentially active candidates targeting LTA4H, which can be useful as anti inflammation agents. Methodology Based on the resolution and the interaction of the co-crystallized ligand in the protein hydrolase and zinc domain part, X-ray crystallographic structure of protein having PDB ID 2VJ8 (with the resolution of 1.80 Å) has been selected from protein data bank [4] for the study, all the molecules were built using builder module of Cerius2 [5] and minimized using the steepest descent algorithm with a convergence gradient value of 0.001 kcal/mol. Docking was done to analyze the ligand-protein interaction with CDOCKER [6] . Pharmacophore generation was done in Catalyst 4.10 program [7] .
Pharmacophore Generation
For the pharmacophore modeling studies, a set of LTA4H inhibitory activity data (IC50) spanning over 4 orders of magnitude (from 1 to 630,000 nM) were selected [8] [9] [10] [11] [12] [13] . The dataset was divided into training set (Insert Fig 1) and test set (supplementary information Table1). Some inactive compounds were also included in order to obtain critical information on pharmacophore requirements. The important aspect of this selection scheme was that each active compound would teach something new to the HypoGen module to help it cover as much critical information as possible for predicting biological activity. To generate 3D pharmacophore, each compound should have conformations to cover International Journal of Drug Discovery, ISSN: 0975-4423, Volume 2, Issue 2, 2010 three dimensional spaces. For this, conformational models of all molecules were generated using the 'best quality' conformational search option within the Catalyst's ConFirm module. It generates the conformations using the Poling' algorithm [14] .
A maximum of 250 conformations were generated for each compound to ensure maximum coverage in the conformational space within default energy threshold of 20 kcal/mol above the global energy minimum. Ten best Pharmacophore (called hypotheses in the program) models were generated using HypoGen module. An initial analysis revealed that four chemical feature types such as hydrogen-bond acceptor (HA), hydrogenbond donor (HD), hydrophobic aliphatic (HPAli), hydrophobic aromatic (HPAr) features could effectively map all critical chemical features of all molecules in the training and test sets. These features were selected and used to build a series of hypotheses using default uncertainty value 3 (defined by Catalyst as the measured value being within three times higher or three times lower of the true value). Indeed, Catalyst generates a chemical-feature-based model on the basis of the most active compounds. These compounds are determined by performing a simple calculation based on the activity and uncertainty. In hypothesis generation, the structure and activity correlations in the training set were rigorously examined. HypoGen identifies features that were common to the active compounds but excludes from the inactive compounds within conformationally allowable regions of space. It further estimates the activity of each training set compound using regression parameters. The parameters are computed by the regression analysis using the relationship of geometric fit value versus the negative logarithm of activity. Greater the geometric fit indicates greater activity prediction of the compound. The fit function does not only check if the feature is mapped or not, it also contains a distance term, which measures the distance that separates the feature on the molecule from the centroid of the hypothesis feature.
Results and Discussion
The pharmacophore model has two hydrogen bond acceptor (HA), two hydrogen-bond donor (HD), and two hydrophobic aromatic (HPAr), (Insert Fig 2) Table 1 .(Insert Table1)The first hypothesis (Hypo1) was the best pharmacophore hypothesis which is characterized by the highest cost difference (53.62), lowest root-mean-square error 
Conclusion
The work in the catalyst presented in the study shows how chemical features hydrogen acceptor, hydrophobic aliphatic of set of compounds along with their activities ranging over several orders of magnitude can be used to generate pharmacophore hypothesis, that can successfully predict the biological activity. The models were not only predictive within the same series of compounds but different classes of diverse compounds also effectively mapped onto most of the features important for activity as they had a good correlation value of 0.92 and a good configuration cost value 13.45. The pharmacophore generated can be used for diversified structures that can be potentially inhibit LTA4H inhibitors discovery and to evaluate how well any newly designed compound maps in the pharmacophore developed in this study, using inhibitors against LTA4H showed distinct features that may be responsible for the activity of the inhibitors. 
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